cisplatin,gemcitabine,nivolumab
bms
['gu ', 'mibc', 'nivolumab', 'cisplatin', 'hcrn,gu,16-257', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo', 'gemcitabine', 'bladder']
co-primary endpoint analysis of hcrn gu 16-257: phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (mibc). #gu23 
Medical Oncologist - Urologic Oncology. Hospital Universitario La Paz - IdiPAZ, Madrid